Page Banner
Mayo Clinic Laboratories > Oncology

The future of comprehensive cancer care

Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.

Upcoming webinar Cytology Specimen Utilization: A Proven Approach to Genetic Sequencing
Answers From the Lab Liquid Biopsy Enables Precision Cancer Care
View now Hematology, oncology, and hereditary test selection guide
Patient spotlight After a rare cancer diagnosis, Alexa Lofaro is reclaiming her independence.
Eye on Innovation In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate.

ONCOLOGY TEST SPECIALTIES

Biopharma testing Biopharma testing
Biopharma testing

Our cancer testing is developed by a team of geneticists, genetic counselors, and physicians, and validated by clinical experts focused on improving patient care and increasing efficiency. Our molecular and cytogenetic assays span the oncological spectrum, providing insights to advance clinical trials and therapeutic development.

Breast and gynecological cancer Breast and gynecological cancer
Breast and gynecological cancer

Our suite of gynecological and breast cancer tests is designed to provide a detailed picture of a patient’s cancer diagnosis, helping clinicians access the information they need to guide care decisions.

Colorectal and gastrointestinal cancer Colorectal and gastrointestinal cancer
Colorectal and gastrointestinal cancer

Our expansive menu of data-driven evaluations detect, identify, and offer specific details on an array of colorectal cancers. Using advanced technologies, including next-generation sequencing and cell-free DNA analysis, our testing is focused, cost-effective, and clinically backed.

Hereditary cancer Hereditary cancer
Hereditary cancer

Our germline test menu includes comprehensive and targeted panels as well as single gene testing. Developed in collaboration with geneticists and genetic counselors, our evaluations examine genes known for their association with cancer risk.

Lung cancer Lung cancer
Lung cancer

We offer comprehensive options for diagnostic, prognostic, and predictive lung cancer testing. Our specimen requirements are optimized to conserve tissue through next-generation sequencing evaluations validated for cytology specimens, which makes results available for more patients.

MayoComplete next-generation sequencing MayoComplete next-generation sequencing
MayoComplete next-generation sequencing

Including comprehensive and disease-specific panels, MayoComplete next-generation sequencing ensures each patient receives the right test and personalized answers to guide their cancer journey. Our comprehensive panel is among the largest currently available and only includes carefully vetted, actionable genes.

Melanoma Melanoma
Melanoma

Our melanoma testing uses next-generation sequencing to identify variants in 17 genes associated with diagnosis, prognosis, and treatment guidance.

Neuro-oncology Neuro-oncology
Neuro-oncology

Backed by a clinical practice recognized for excellence in treating cancer patients, our advanced genetic testing for neuro-oncology cancer combines molecular and cytogenetic analysis to complement standard morphological and histological assessment.

Pediatric cancer Pediatric cancer
Pediatric cancer

Our pediatric oncology testing is designed in collaboration with pediatric oncology experts to deliver individualized insights to confirm diagnosis and guide treatment.

Precision oncology therapeutics Precision oncology therapeutics
Precision oncology therapeutics

Browse our suite of personalized cancer testing that’s been developed by experts to establish patients’ genetic profiles and allow physicians to optimize therapeutic efficacy while simultaneously minimizing harmful reactions.

Sarcoma Sarcoma
Sarcoma

We’ve met the challenge of diagnosing sarcoma through development of a comprehensive sarcoma fusion panel, which improves diagnostic accuracy and overall patient management.

Urologic cancer Urologic cancer
Urologic cancer

Our genitourinary cancer panels use next-generation sequencing to evaluate genes with known relevance to diagnosis, prognosis, and treatment of renal cell carcinoma and bladder and prostate cancers. Carefully designed by an integrated team of clinical experts, geneticists, and genetic counselors, our panels include only clinically actionable genes.

“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”

Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics

Our difference

Clinically meaningful oncology testing
Encompassing more than 100 solid tumor evaluations, our testing provides diagnostic and prognostic answers to help guide treatment selection across the spectrum of malignancies by only including genes proven to impact patient outcomes. This eliminates confusing results, decreases the cost of testing, and leads to better patient care.

Integrated care for patients with cancer
We’ve taken the lead in designing and optimizing testing to guide patient care based on specific tumors. Our experience with clinical care is integrated with our expertise in pathology, genetics, and bioinformatics to direct gene selection for each panel and how these panels are used in a clinical setting.

Turning complex genetic results into actionable insights
Including more than 20 board-certified geneticists specializing in molecular and cytogenic diagnostic testing, our integrated team of clinical, genetic, and laboratory testing experts is available 24/7 to provide expertise and consultative support, removing the guesswork from test selection and results interpretation.

News and updates

The latest

Upcoming webinar: Revolutionizing cancer diagnosis with LiquidHALLMARK® featured image
Upcoming webinar: Revolutionizing cancer diagnosis with LiquidHALLMARK®

Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.

Learn more
Arresting Melanoma’s Molecular Drivers

Melanoma, the skin cancer often associated with sun exposure, is on the rise and has no reliable cure. Mayo Clinic is at the forefront of these efforts. The Center for Individualized Medicine is unraveling the complex behavior of melanoma at the molecular level—to allow for treatment that better targets an individual's disease.

The Prostate Health Index <i>(PHI)</i> in Prostate Cancer Risk Assessment

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

Prostate Health Index (phi) [Test in Focus]

Useful For     Video Overview Clinical Information Several PSA isoforms have been identified that can further increase the specificity of PSA for prostate cancer.[...]

Resources
Download Oncology test request form
View now Hematology, oncology, and hereditary test selection guide
Delivering specialized testing and consultative support for:
Learn more Commercial laboratories
Learn more Global healthcare
Learn more Hospitals and health systems

LEARN MORE ABOUT HOW WE CAN BUILD YOUR LAB'S POTENTIAL.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.